Appendix 4C & Activity Report
Melbourne, Australia, 31 January 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreTechnical Note: Developing a melanocortin pipeline
CLINUVEL today announced an update on its commercial development of the analogue...
Read MoreNEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read MoreMedia release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results from a clinical trial in a genetic DNA repair disorder show...
Read MoreAfamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note
Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreAfamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More